Julio Chavez, MD

Dr. Chavez explains that for most patients with relapsed/refractory DLBCL in the third-line setting, including those who are not CAR T candidates, decline CAR T, or progress after CAR T, bispecific antibodies are his preferred option.

Dr. Chavez reviews glofitamab, the second bispecific antibody approved for relapsed/refractory DLBCL, and compares its pivotal data with those of epcoritamab.

Drs Chavez and Phillips discuss practical considerations beyond CRS and ICANS for patients with relapsed/refractory DLBCL receiving bispecific antibodies.

Dr. Phillips reviews the pivotal EPCORE NHL-1 trial of subcutaneous epcoritamab in heavily pretreated relapsed/refractory large B-cell lymphoma, including patients with prior CAR T-cell therapy and double-hit disease.

Julio C. Chavez, MD, of Mayo Clinic in Jacksonville, Florida, and Tycel Phillips, MD, of City of Hope in Duarte, California, open their discussion by outlining the treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in the third-line setting.

Julio Chavez, MD, assistant member, Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center, discusses the use of blinatumomab (Blincyto) in patients with acute lymphoblastic leukemia (ALL).

Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses the potential with the combination of ibrutinib (Imbruvica) and ublituximab (TGR-1101) in patients with chronic lymphocytic leukemia (CLL).

Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, shares his advice for oncologists treating patients with chronic lymphocytic leukemia.

Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses ibrutinib (Imbruvica) plus venetoclax (Venclexta) in chronic lymphocytic leukemia.

Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses the ongoing efficacy but also challenges with ibrutinib (Imbruvica) as treatment for patients with chronic lymphocytic leukemia (CLL).